CliffBio
small molecule

AIRDUO DIGIHALER

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Loss of exclusivityJanuary 2041latest FDA-listed patent expiry
CompanyTeva Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameAIRDUO DIGIHALER
Active ingredientFLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
Strength0.113MG/INH;EQ 0.014MG BASE/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalJuly 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
11173259*PEDJanuary 2041—
11173259July 2040product
11344685*PEDMarch 2040—
11969544*PEDFebruary 2040—
11344685September 2039product
11969544August 2039product
10918816*PEDJune 2036—
10918816December 2035product
9066957*PEDApril 2035—
9066957October 2034product
10195375*PEDAugust 2031—
10195375February 2031product

More from Teva Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AIRDUO DIGIHALER patent cliff — loss of exclusivity January 2041 | CliffBio